Clinical Trial Update: Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating switching virologically suppressed HIV-1 patients from a ritonavir-boosted protease inhibitor plus emtricitabine/tenofovir disoproxil f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• HIV Infection

Drugs mentioned

• Cobicistat (cobicistat)
• Emtricitabine (Emtricitabine)
• Ritonavir (Ritonavir)
• TENOFOVIR DISOPROXIL FUMARATE (tenofovir disoproxil fumarate)
• elvitegravir (elvitegravir)

Snippet

Sponsor: Gilead Sciences | Conditions: Acquired Immunodeficiency Syndrome, HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2015-01-26